AF9 antibody (Middle Region)

Catalog No. ABIN358674

Product Details anti-AF9 Antibody

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Binding Specificity: Middle Region

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This AF9 antibody is un-conjugated

Application: Western Blotting (WB), Enzyme Immunoassay (EIA)

Specificity: This antibody reacts to AF9 (MLLT3).

Purification: Prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS

Immunogen: This antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the center region of human MLLT3.

Isotype: Ig Fraction

Application Details

Application Notes: ELISA: 1/1,000. Western blotting: 1/100 - 1/500.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.25 mg/mL

Buffer: PBS with 0.09 % (W/V) sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Avoid repeated freezing and thawing.

Storage: 4 °C/-20 °C

Storage Comment: Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.

Target Details for AF9

Target: AF9 (MLLT3) (Protein AF-9 (MLLT3))

Alternative Name: MLLT3 / AF9 (MLLT3 Products)

Synonyms: fc39c11 antibody, wu:fc39c11 antibody, zgc:110210 antibody, AF9 antibody, YEATS3 antibody, 2210011H10Rik antibody, 2610012I03Rik antibody, 3830408D16Rik antibody, Af9 antibody, D4Ertd321e antibody, Af-9 antibody, MLLT3, super elongation complex subunit antibody, myeloid/lymphoid or mixed-lineage leukemia; translocated to, 3 antibody, mllt3 antibody, MLLT3 antibody, Mllt3 antibody

Background: The human AF9 gene is one of the most common fusion partner genes with the ALL1 gene at 11q23 (also called MLL), resulting in the t(9,11)(p22,q23). The AF9 gene is more than 100 kb, and 2 patient breakpoint cluster regions (BCRs) have been identified, BCR1 is within intron 4, previously called site A, whereas BCR2 or site B spans introns 7 and 8. Several different structural elements have been identified in AF9, including a colocalizing in vivo DNA topo II cleavage site and an in vitro DNase I hypersensitive (DNase 1 HS) site in intron 7 in BCR2. Reversibility experiments demonstrated a religation of the topo II cleavage sites. In addition, 2 scaffold associated regions (SARs) are located centromeric to the topo II and DNase I HS cleavage sites and border breakpoint regions in 2 leukemic cells lines: SAR1 is located in intron 4, whereas SAR2 encompasses parts of exons 5-7. The patient breakpoint regions of AF9 share the same structural elements as the MLL BCR. A DNA breakage and repair model for nonhomologous recombination between MLL and its partner genes, particularly AF9, has been proposed.Synonyms: ALL1 fused gene from chromosome 9 protein, Myeloid/lymphoid or mixed-lineage leukemia translocated to chromosome 3 protein, Protein AF-9, YEATS domain-containing protein 3, YEATS3

Gene ID: 4300, 9606

UniProt: P42568